Phase 2 study update lifts Merck stock amid overbought signals and bullish trend

Traders Union
All News
Companies
Merck gains 0.66% today at $119.71

Highlights

MRK is exhibiting strong bullish momentum, trading well above all major moving averages and near the top of its weekly range.
Technical indicators show the stock is overbought in the short term, with dominant buyer pressure and signs of near-term exhaustion.
For the coming week, MRK is expected to consolidate between $118.30 and $121.84, with a breakout above $121.84 targeting the 52-week high of $125.14.

MRK is trading above all major moving averages on D1, standing at $119.71, which is higher than the 20-day SMA ($116.96), the 50-day SMA ($116.45), and the 200-day SMA ($95.61). This positioning confirms bullish momentum on short-, medium-, and long-term time horizons, while the Ichimoku Kijun at $118.94 acts as immediate support for the current price. Near-term support is clustered at the MA-20 ($116.96), while key support is the MA-100 ($108.13). Immediate resistance is thin above current levels, with key resistance at the MA-5/EMA cluster ($118.01–$118.23) already surpassed, making the next notable barrier the 52-week high ($125.14).

Momentum signals are mixed: MACD and ADX on D1 are neutral, while RSI is positive at 58.99 and CCI registers as overbought. Stoch RSI and BBP both reflect overbought and dominant buyer pressure, highlighting short-term exhaustion. The Awesome Oscillator is neutral on D1 and does not reinforce the trend. Over the past week, MRK has climbed from a previous close of $113.89 to $119.71, a gain of $5.82 or 5.11%. The price is currently at the top of its weekly range ($121.06 high), indicating a strong run-up, with weekly volatility at 6.17%. This suggests momentum has driven MRK into overbought territory, and consolidation or a pause is likely after such a steep move.

For the coming week, the expected trading range is $118.30 to $121.84, keeping MRK well within its recent highs and far above its 52-week low of $73.31, but still below the year’s peak of $125.14. Probabilities favor further gains, with a high likelihood (more than 80%) of a price increase given strong buy signals from the W1 MA-50, RSI W1, ADX W1, and MACD W1, while the probability of a decline is very low. Baseline scenario: MRK consolidates between $118.30 and $121.84 as recent overbought signals work off. Bullish scenario: a break above $121.84 could quickly target the 52-week high at $125.14. Bearish scenario: a drop below $118.30 may find next support near $116.45, with additional downside arrested by longer-term moving averages.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Merck’s acquisition of Terns Pharmaceuticals was seen as a strategic move to bolster its hematology portfolio amid prevailing stock weakness. In light of the current developments, investors should closely watch for signs of sustained momentum or reversal, as these will define Merck’s near-term risk and opportunity profile.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.